leronlimab + pembrolizumab + sacituzumab govitecan

The combination of leronlimab, pembrolizumab, and sacituzumab govitecan is an investigational therapeutic regimen being evaluated for the treatment of metastatic triple-negative breast cancer (mTNBC). Leronlimab is a humanized IgG4 monoclonal antibody that acts as a CCR5 antagonist, designed to modulate the tumor microenvironment and reverse immunosuppression. Pembrolizumab is an anti-PD-1 immune checkpoint inhibitor that enhances T-cell-mediated anti-tumor immune responses. Sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate (ADC) carrying a topoisomerase I inhibitor payload (SN-38) to deliver cytotoxic therapy directly to cancer cells. This combination is being evaluated in the Phase 1-1b PRE5 study within the Quantum Leap Healthcare Collaborative's (QLHC) PRE-I-SPY platform to assess safety, tolerability, and preliminary clinical activity in patients with mTNBC, particularly those with low PD-L1 expression (CPS < 10).